Escalon Medical Corp. Reports $2.37M Net Income Amid Revenue Decline in Q1 2026

Escalon Medical Corp. reported a net income of $2.37 million for the three months ended March 31, 2026, a significant increase from the $271,472 recorded in the same period the previous year. This surge in profitability was primarily driven by a gain of $2.81 million from the sale of its AXIS software, which was not present in the prior year’s results. However, total revenues for the quarter decreased by approximately 24.9% to $2.61 million, down from $3.47 million in the same quarter of 2025. The decline in revenue was attributed to reduced sales in Sonomed and Trek products, as well as a decrease in digital service revenue, reflecting challenges in product fulfillment and shifting demand.

For the nine months ending March 31, 2026, Escalon's total revenues also fell by 6.3% to $8.88 million compared to $9.48 million in the prior year. The decrease was largely due to a $310,000 drop in Sonomed product sales and a $305,000 decline in Trek product sales. The company’s cost of revenue increased to 59.2% of total revenue, up from 53.7% in the previous year, primarily due to changes in product mix and a retention and severance accrual related to the AXIS software sale. Marketing, general, and administrative expenses rose by 10.2% to $3.77 million, driven by higher payroll and fringe benefits, bonuses, and legal expenses.

Escalon's balance sheet showed a notable improvement, with total assets increasing to $7.53 million as of March 31, 2026, compared to $4.99 million at the end of June 2025. This growth was supported by a significant increase in cash and cash equivalents, which rose to $3.34 million from $546,000. The company’s working capital also improved, reaching $4.03 million, reflecting a current ratio of 2.59 to 1, up from 1.72 to 1 in the prior period. The increase in liquidity was primarily due to the proceeds from the AXIS software sale, which bolstered cash reserves.

Operationally, Escalon faced challenges with product fulfillment, particularly in its Sonomed division, which experienced backorders due to vendor constraints. The company is actively pursuing strategic partnerships and cost-cutting measures to enhance its operational efficiency and address ongoing market uncertainties, including the impact of tariffs on its supply chain. Despite the recent profitability, Escalon continues to face substantial doubt regarding its ability to sustain operations without additional capital, as it has historically incurred losses and negative cash flows from operations.

Looking ahead, Escalon Medical Corp. remains focused on enhancing its product offerings and exploring new market opportunities while managing costs. The company is evaluating potential impacts from recent tariffs and trade measures, which could affect its supply chain and profitability. Management is committed to monitoring these developments closely and adapting its strategies to ensure long-term sustainability and growth.